Revelation Biosciences shares are trading lower by 38% during Tuesday's session. The company agreed to a $4M warrant exercise, closing December 3.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...